HIF1α/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hypoxia-inducible factor 1α (HIF-1α) and programmed cell death-1 protein ligand 1 (PD-L1) are implicated in the metastasis and progression processes of multiple cancers. Hypoxia selectively elevates PD-L1 expression via HIF1α activation in several solid tumors; however, the regulatory effect of HIF1α on PD-L1 in the pathogenesis of follicular thyroid cancer (FTC) remains unclear. This study aims to investigate the regulatory effect of HIF1α on PD-L1 and their potential roles in FTC pathogenesis. METHODS: Spearman correlation analysis was performed to clarify the relationships between HIF1α and PD-L1 expressions and the clinicopathologic characteristics. The expressions of HIF1α and PD-L1 at mRNA and protein levels were analyzed by qRT-PCR and Western blot. Hypoxia induction and cell transfection were conducted in FTC cells. TUNEL and Annexin V staining were used to detect the cell apoptosis. FTC xenograft tumor models were generated to evaluate the roles of HIF1α and PD-L1 in vivo. RESULTS: Here, we found that the expressions of HIF1α and PD-L1 were significantly increased in FTC tissues and were correlated with the FTC clinicopathologic features, such as the tumor size, T stage, TNM staging, and metastasis. In FTC cells, hypoxia-induced increased HIF1α and PD-L1 expression. Knockdown of HIF1α inhibits hypoxia-induced PD-L1 expression and cells apoptosis. Moreover, inhibition of HIF1α or PD-L1 significantly delays tumor growth and metastasis in vivo. CONCLUSION: Hypoxia could promote FTC progression by upregulating HIF1α and PD-L1, which could serve as the molecular targets for FTC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · cited 1×
“High expression of PDL1 in tumors is closely associated with cancer immune evasion and often regarded as a negative prognostic factor.(9) It has been claimed that the expression of PD-L1 and PD-1 was significantly correlated with prognosis of FTC patients, suggesting an effective immunotherapy for FTC treatment FTC by…”
BackgroundHypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
Marchiq, I., & Pouysségur, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1307-x · Cited by 300 · cited 1×
“By mediating oncogene activation and loss of tumor suppressors, hypoxia plays a crucial role in tumor cell invasion, metastasis, and progression.(2) In response to hypoxia situation, hypoxia-inducible factor (HIF) is upregulated to coordinate an appropriated adaptive response.”
BackgroundPD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 298 · cited 3×
“PD-L1 is the primary ligand of PD-1.”
BackgroundHypoxia-inducible factor 1 and breast cancer metastasis
Liu, Z.-J., Semenza, G. L., & Zhang, H.-F. (2015) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b1400221 · Cited by 252 · cited 1×
“Via regulating noncoding RNAs, HIF1α highly contributes to breast cancer metastasis.(20) In this study, we firstly analyze the correlation between HIF1α and FTC clinicopathologic features and revealed that HIF1α expression is correlated with TNM staging and metastasis.”
BackgroundChowdhury, S., Veyhl, J., Jessa, F., Polyakova, O., Alenzi, A., MacMillan, C., Ralhan, R., & Walfish, P. G. (2016) · Oncotarget · doi:10.18632/oncotarget.8698 · Cited by 193
Hypoxia and cellular metabolism in tumour pathophysiology
Parks, S. K., Cormerais, Y., & Pouysségur, J. (2017) · The Journal of Physiology · doi:10.1113/jp273309 · Cited by 142 · cited 1×
“Due to the rapid proliferation of tumor cells and the abnormality of tumor vessels in function and structure, the hypoxic areas widely exist in solid tumors.(15,16) By transcriptionally activating diverse targeting genes, HIF functions as a”
BackgroundHypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
Huang, Y., Lin, D., & Taniguchi, C. M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9178-y · Cited by 142 · cited 1×
“major adaptive mechanism in tumor growth response to a hypoxic microenvironment, occupying a pivotal position in tumorigenesis.(17,18) In African breast cancer, high HIF1α expression is a significant marker of poor prognosis.”
BackgroundChang, Y., Yang, C., Lin, M., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.012 · Cited by 126
Self-citation
Cited by
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
“Besides inflammatory cytokines extrinsically modulating PD-L1 expression, hypoxia in the tumor microenvironment selectively elevates PD-L1 expression viaHIF1α activation in melanoma, breast, lung, thyroid and prostate cancer (9, 146, 167).”
BackgroundYuan, Z., Fan, G., Wu, H., Liu, C., Zhan, Y., Qiu, Y., Shou, C., Gao, F., Zhang, J., Yin, P., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.017 · Cited by 141
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115
Metadata
- Authors
- Zhou, L., Cha, G., Chen, L., Yang, C., Xu, D., & Ge, M.
- Affiliations
- Chinese Academy of Sciences (CN)
- Quzhou City People's Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Corresponding author
- Xu, Dong
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-08
- Volume
- Volume 12
- Pages
- 6461-6470
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6698605
- OpenAlex
- W2967571151
- Semantic Scholar
- 7d43e93b813a3c04f2503f7b10646f7ad9aed149
- Cited by
- 34
- References
- 25
- Citations by year
- 2026: 1 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 11
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2022-11-21)
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- HIF-1α, PD-L1, follicular thyroid carcinoma, tumor hypoxia, apoptosis, tumor progression, metastasis, tumor growth, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.